… pathways upon PI3K inhibitor monotreatment. In … SHP2 induced resistance to PI3K inhibition,
and that SHP2 was frequently activated during the development of PI3K inhibitor resistance …

… resistant to SHP2 inhibitors. We further show that combinations of SHP2 inhibitors with other
RAS-MAPK pathway inhibitors, such … NRAS resistance to SHP2 inhibitors is reversed when …

… context of SHP2 inhibition and discovered that the kinase ITK is a SHP2 target specifically
… of PD-1, and not the TCR, and that its dephosphorylation is associated with T cell inhibition. …

… SHP2-dependent systemic toxicity. The objective of this study was to investigate whether
the combination of a SHP2 inhibitor (… outcomes are limited by tumour resistance 19,20,21 . …

… sorafenib-resistant cell lines have much higher levels of SHP2. … SHP2 inhibitor SHP099 may
eradicate sorafenib resistance … SHP2 inhibition decreases adaptive resistance to sorafenib …

… the resulting adaptive resistance to targeted kinase inhibition. Plasticity of … adaptive tumor
cell drug resistance. The dynamic transcriptional nature of the kinome also differs for inhibitors …

… Unfortunately, in vivo models of breast cancer treated with this or similar inhibitors have
identified the induction of acquired resistance, mainly due to activation of HER2 receptor tyrosine …

… program directed at allosteric SHP2 inhibitors, we conducted … of our previously disclosed
SHP2 inhibitor 2 with the SHP2-… 2a) broadly characterized SHP2 allosteric pocket ligands as …

… Shp2 inhibition in the liver immune environment. We provide a proof of principle for clinical
trials with specific Shp2 inhibitors in patients with primary and metastasized liver cancer. …

… the commonly used SHP2 inhibitor NSC-87877 does not exhibit robust inhibitory effects on
… indicate that SHP2 deficiency blocks adaptive resistance to RAF inhibitors [16], and SHP2 is …